ER positive	Estrogen Receptor Positive Breast Cancer	ER positive	Estrogen Receptor Positive Breast Cancer	fulvestrant Sensitive: A1 - Approval fulvestrant Sensitive : A1	fulvestrant Sensitive: A1 - Approval fulvestrant Sensitive : A1
ER positive	Estrogen Receptor Positive Breast Cancer	ER positive	Estrogen Receptor Positive Breast Cancer	exemestane Sensitive: A1 - Approval exemestane Sensitive : A1	exemestane Sensitive: A1 - Approval exemestane Sensitive : A1
ER positive	Estrogen Receptor Positive Breast Cancer	ER positive	Estrogen Receptor Positive Breast Cancer	toremifene Sensitive: A1 - Approval toremifene Sensitive : A1	toremifene Sensitive: A1 - Approval toremifene Sensitive : A1
ER positive	Estrogen Receptor Positive Breast Cancer	ER positive	Estrogen Receptor Positive Breast Cancer	goserelin acetate Sensitive: A1 - Approval goserelin acetate Sensitive : A1	goserelin acetate Sensitive: A1 - Approval goserelin acetate Sensitive : A1
ER mutation	Estrogen Receptor Positive Breast Cancer	ER mutation	Estrogen Receptor Positive Breast Cancer	palbociclib Sensitive: B - Late Trials palbociclib Sensitive : B	palbociclib Sensitive: B - Late Trials palbociclib Sensitive : B
ER positive	Estrogen Receptor Positive Breast Cancer	ER positive	Estrogen Receptor Positive Breast Cancer	palbociclib Sensitive: B - Late Trials palbociclib Sensitive : B	palbociclib Sensitive: B - Late Trials palbociclib Sensitive : B
ER mutation	Estrogen Receptor Positive Breast Cancer	ER mutation	Estrogen Receptor Positive Breast Cancer	fulvestrant Sensitive: B - Late Trials fulvestrant Sensitive : B	fulvestrant Sensitive: B - Late Trials fulvestrant Sensitive : B
ER mutation	Estrogen Receptor Positive Breast Cancer	ER mutation	Estrogen Receptor Positive Breast Cancer	exemestane Resistant: B - Late Trials exemestane Resistant : B	exemestane Resistant: B - Late Trials exemestane Resistant : B
HSD17B2 overexpression	Estrogen Receptor Positive Breast Cancer	HSD17B2 overexpression	Estrogen Receptor Positive Breast Cancer	tamoxifen Sensitive: B - Late Trials tamoxifen Sensitive : B	tamoxifen Sensitive: B - Late Trials tamoxifen Sensitive : B
IGFBP7 overexpression	Estrogen Receptor Positive Breast Cancer	IGFBP7 overexpression	Estrogen Receptor Positive Breast Cancer	tamoxifen Sensitive: B - Late Trials tamoxifen Sensitive : B	tamoxifen Sensitive: B - Late Trials tamoxifen Sensitive : B
ER positive	Estrogen Receptor Positive Breast Cancer	ER positive	Estrogen Receptor Positive Breast Cancer	elacestrant Sensitive: B - Late Trials elacestrant Sensitive : B	elacestrant Sensitive: B - Late Trials elacestrant Sensitive : B
ESR1 mutation	Estrogen Receptor Positive Breast Cancer	ESR1 mutation	Estrogen Receptor Positive Breast Cancer	palbociclib Sensitive: B - Late Trials palbociclib Sensitive : B	palbociclib Sensitive: B - Late Trials palbociclib Sensitive : B
ER positive	Estrogen Receptor Positive Breast Cancer	ER positive	Estrogen Receptor Positive Breast Cancer	Z-endoxifen hydrochloride Sensitive: C2 – Inclusion Criteria Z-endoxifen hydrochloride Sensitive : C2	Z-endoxifen hydrochloride Sensitive: C2 – Inclusion Criteria Z-endoxifen hydrochloride Sensitive : C2
ER positive	Estrogen Receptor Positive Breast Cancer	ER positive	Estrogen Receptor Positive Breast Cancer	SAR439859 Sensitive: C2 – Inclusion Criteria SAR439859 Sensitive : C2	SAR439859 Sensitive: C2 – Inclusion Criteria SAR439859 Sensitive : C2
ER positive	Estrogen Receptor Positive Breast Cancer	ER positive	Estrogen Receptor Positive Breast Cancer	trastuzumab + pertuzumab Sensitive: C2 – Inclusion Criteria trastuzumab + pertuzumab Sensitive : C2	trastuzumab + pertuzumab Sensitive: C2 – Inclusion Criteria trastuzumab + pertuzumab Sensitive : C2
ER positive	Estrogen Receptor Positive Breast Cancer	ER positive	Estrogen Receptor Positive Breast Cancer	alpelisib Sensitive: C2 – Inclusion Criteria alpelisib Sensitive : C2	alpelisib Sensitive: C2 – Inclusion Criteria alpelisib Sensitive : C2
ER positive	Estrogen Receptor Positive Breast Cancer	ER positive	Estrogen Receptor Positive Breast Cancer	venetoclax Sensitive: C2 – Inclusion Criteria venetoclax Sensitive : C2	venetoclax Sensitive: C2 – Inclusion Criteria venetoclax Sensitive : C2
BCL2 positive	Estrogen Receptor Positive Breast Cancer	BCL2 positive	Estrogen Receptor Positive Breast Cancer	venetoclax Sensitive: C2 – Inclusion Criteria venetoclax Sensitive : C2	venetoclax Sensitive: C2 – Inclusion Criteria venetoclax Sensitive : C2
ER positive	Estrogen Receptor Positive Breast Cancer	ER positive	Estrogen Receptor Positive Breast Cancer	abemaciclib Sensitive: C2 – Inclusion Criteria abemaciclib Sensitive : C2	abemaciclib Sensitive: C2 – Inclusion Criteria abemaciclib Sensitive : C2
ER positive	Estrogen Receptor Positive Breast Cancer	ER positive	Estrogen Receptor Positive Breast Cancer	ribociclib Sensitive: C2 – Inclusion Criteria ribociclib Sensitive : C2	ribociclib Sensitive: C2 – Inclusion Criteria ribociclib Sensitive : C2
ER mutation	Estrogen Receptor Positive Breast Cancer	ER mutation	Estrogen Receptor Positive Breast Cancer	elacestrant Sensitive: C2 – Inclusion Criteria elacestrant Sensitive : C2	elacestrant Sensitive: C2 – Inclusion Criteria elacestrant Sensitive : C2
PTEN mutation	Estrogen Receptor Positive Breast Cancer	PTEN mutation	Estrogen Receptor Positive Breast Cancer	capivasertib Sensitive: C2 – Inclusion Criteria capivasertib Sensitive : C2	capivasertib Sensitive: C2 – Inclusion Criteria capivasertib Sensitive : C2
AR positive	Estrogen Receptor Positive Breast Cancer	AR positive	Estrogen Receptor Positive Breast Cancer	enobosarm Sensitive: C2 – Inclusion Criteria enobosarm Sensitive : C2	enobosarm Sensitive: C2 – Inclusion Criteria enobosarm Sensitive : C2
ER positive	Estrogen Receptor Positive Breast Cancer	ER positive	Estrogen Receptor Positive Breast Cancer	tamoxifen Sensitive: C2 – Inclusion Criteria tamoxifen Sensitive : C2	tamoxifen Sensitive: C2 – Inclusion Criteria tamoxifen Sensitive : C2
ER positive	Estrogen Receptor Positive Breast Cancer	ER positive	Estrogen Receptor Positive Breast Cancer	anastrozole Sensitive: C2 – Inclusion Criteria anastrozole Sensitive : C2	anastrozole Sensitive: C2 – Inclusion Criteria anastrozole Sensitive : C2
ER positive	Estrogen Receptor Positive Breast Cancer	ER positive	Estrogen Receptor Positive Breast Cancer	letrozole Sensitive: C2 – Inclusion Criteria letrozole Sensitive : C2	letrozole Sensitive: C2 – Inclusion Criteria letrozole Sensitive : C2
ER positive	Estrogen Receptor Positive Breast Cancer	ER positive	Estrogen Receptor Positive Breast Cancer	RG4733 Sensitive: C2 – Inclusion Criteria RG4733 Sensitive : C2	RG4733 Sensitive: C2 – Inclusion Criteria RG4733 Sensitive : C2
ER positive	Estrogen Receptor Positive Breast Cancer	ER positive	Estrogen Receptor Positive Breast Cancer	entinostat Sensitive: C2 – Inclusion Criteria entinostat Sensitive : C2	entinostat Sensitive: C2 – Inclusion Criteria entinostat Sensitive : C2
ER positive	Estrogen Receptor Positive Breast Cancer	ER positive	Estrogen Receptor Positive Breast Cancer	tamoxifen + goserelin acetate Sensitive: C2 – Inclusion Criteria tamoxifen + goserelin acetate Sensitive : C2	tamoxifen + goserelin acetate Sensitive: C2 – Inclusion Criteria tamoxifen + goserelin acetate Sensitive : C2
TP53 wild-type	Estrogen Receptor Positive Breast Cancer	TP53 wild-type	Estrogen Receptor Positive Breast Cancer	ALRN-6924 Sensitive: C2 – Inclusion Criteria ALRN-6924 Sensitive : C2	ALRN-6924 Sensitive: C2 – Inclusion Criteria ALRN-6924 Sensitive : C2
ER positive	Estrogen Receptor Positive Breast Cancer	ER positive	Estrogen Receptor Positive Breast Cancer	Immunotherapy + fulvestrant Sensitive: C2 – Inclusion Criteria Immunotherapy + fulvestrant Sensitive : C2	Immunotherapy + fulvestrant Sensitive: C2 – Inclusion Criteria Immunotherapy + fulvestrant Sensitive : C2
EPRS1 expression	Estrogen Receptor Positive Breast Cancer	EPRS1 expression	Estrogen Receptor Positive Breast Cancer	tamoxifen Sensitive: C3 – Early Trials tamoxifen Sensitive : C3	tamoxifen Sensitive: C3 – Early Trials tamoxifen Sensitive : C3

Estrogen Receptor Positive Breast Cancer

Associations(221)

Associations
(221)